Executive Summary
Strategic scoping and focus
Datamonitor insight into the urinary incontinence market
Related reports
OVERVIEW
Catalyst
Summary
EPIDEMIOLOGY
Introduction
Key findings
Disease definition, classification and diagnosis criteria
Risk factors
Age
Gender
Pregnancy/Childbirth
Race
Obesity
Hysterectomy
Smoking
Co-morbidities
Global variation and temporal trends
Epidemiologic forecasting of urinary incontinence methodology
Sources of epidemiologic data
Description of methods
Results
Urinary incontinence
Stress urinary incontinence
Urge urinary incontinence
Mixed urinary incontinence
Other urinary incontinence
Discussion
Strengths of Datamonitor’s epidemiologic projections
Conclusions
TREATMENT OVERVIEW
Key findings
Overview of urinary incontinence
Normal bladder function
Urinary incontinence
Treatment overview
Behavioral techniques
Physical therapy
Pharmacological treatment
Medical devices
Non surgical procedures
Surgery
Unmet need in urinary incontinence
Need for alternative mechanisms of action
Need for improved compliance
Need for improved efficacy over side effects profile
Need for medical treatment for stress urinary incontinence
Need for on-demand use drugs
Target product profile versus current level of attainment
MARKET OVERVIEW
Key findings
Market definition for this report
Seven major markets
Current and future market overview
US
Current and future market assessment
Japan
Current and future market assessment
Five major European markets (5EU)
Current and future market assessment
France
Current and future market assessment
Germany
Current and future market assessment
Italy
Current and future market assessment
Spain
Current and future market assessment
UK
Current and future market assessment
Rest of the world snapshot
Current market assessment
BRAND DYNAMICS
Key findings
Overview of competitive landscape
Me too drugs battle for market share
Patient acquisition process
Introduction
Patient care path
Points of influence in the patient care path
Drivers of brand choice
US formulary tier status for leading brands
Trends in marketing strategies
Marketing strategy for leading brands
Patient support groups
Sponsorship/disease awareness campaigns
Direct-to-consumer advertising
Detrol/Detrol LA (tolterodine tartrate; Pfizer) – Comparator therapy
Drug profile
SWOT analysis
Product positioning
Brand forecast to 2019
Toviaz (fesoterodine fumarate; Pfizer)
Drug profile
SWOT analysis
Product positioning
Brand forecast to 2019
Vesicare (solifenacin succinate; Astellas/GlaxoSmithKline)
Drug profile
SWOT analysis
Product positioning
Brand forecast to 2019
Enablex (darifenacin hydrobromide; Novartis/Warner Chilcott)
Drug profile
SWOT analysis
Product positioning
Brand forecast to 2019
Sanctura/Sanctura XR (trospium chloride; Endo Pharmaceuticals/Rottapharm/Allergan)
Drug profile
SWOT analysis
Product positioning
Brand forecast to 2019
Oxytrol/Kentera (oxybutynin transdermal patch; Watson/Recordati)
Drug profile
SWOT analysis
Product positioning
Brand forecast to 2019
Gelnique (oxybutynin gel; Watson)
Drug profile
SWOT analysis
Product positioning
Brand forecast to 2019
Yentreve (duloxetine; Eli Lilly)
Drug profile
SWOT analysis
Product positioning
Brand forecast to 2019
Other marketed drugs
Ditropan/Ditropan XL (oxybutynin; Alza)
Mictonorm/Detrunorm/BUP-4 (propiverine; UCB/ Amdipharm)
Uritos/Staybla (imidafenacin; Kyron/Ono Pharmaceuticals/Eisai)
PIPELINE OVERVIEW AND R&D DYNAMICS
Key findings
Pipeline overview
Clinical pipeline
Classification of pipeline
Comparative forecasts
Datamonitor pipeline assessment summary
Clinical trial design
Clinical trial endpoints in urinary incontinence
Assessment of clinical trial endpoints
PIPELINE ANALYSIS & FORECASTS
Key findings
Overview
Pipeline summary
Comparative forecasts
Mirabegron (YM178; Astellas Pharma)
Drug overview
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for mirabegron
Clinical and commercial attractiveness
Forecasts to 2019
Botox (botulinum toxin A; Allergan)
Drug overview
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for Botox
Clinical and commercial attractiveness
Forecasts to 2019
Anturol ATD (oxybutynin gel; Antares)
Drug overview
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for Anturol ATD
Clinical and commercial attractiveness
Forecasts to 2019
HOB294 (oxybutynin chloride patch; Hisamitsu Pharmaceutical)
Drug overview
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for HOB294
Clinical and commercial attractiveness
Forecasts to 2019
Other drugs in development for urinary incontinence
DR3001 (Teva)
KUC-7483 (ritobegron; Kissei)
Solabegron (AltheRx Pharmaceuticals)
PSD503 (phenylephrine; Plethora Solutions)
SMP-986 (Dainippon Sumitomo Pharma)
MCP-101 (resiniferatoxin; Mt Cook Pharma)
Ono-8539 (Ono Pharmaceutical)
SVT40776 (tarafenacin; Laboratorios Salvat)
PSD506 (phenylephrine; Plethora Solutions)
RCD1 (HRA Pharma/Celegos)
KN203 (KeyNeurotek)
FP1097 (oxybutynin vaginal; FemmePharma Global Healthcare)
KEY DEVELOPERS
Key findings
Strategic overview
Big Pharma dominate the market
Trends in corporate strategy
Recent strategic partnerships/deals
Pfizer
Corporate strategy
Urinary incontinence portfolio assessment
Astellas
Corporate strategy
Urinary incontinence portfolio assessment
BIBLIOGRAPHY
Epidemiology
Journal papers
Treatment overview
Journal papers
Websites
Brand Dynamics
Journal papers
Websites
Pipeline overview
Journal papers
Websites
Pipeline Dynamics
Journal papers
Websites
Key Developers
Datamonitor reports
APPENDIX A – MARKET ASSUMPTIONS
Forecasting assumptions
New product launches
Patent expiries
Data definitions, limitations and assumptions
Standard units
Derivation of sales forecasts and pricing trends
Exchange rates
Country group definitions
Derivation of sales forecasts and pricing trends
Forecast methodology
APPENDIX B
Contributing experts
Conferences attended
Report methodology
[Inhaltsverzeichnis ausblenden]